The prevalence of psoriasis in African Americans: Results from a population-based study - 21/08/11
, Robert S. Stern, MD b, Tamar Nijsten, MD c, Steven R. Feldman, MD, PhD d, John Thomas, MS e, Joe Kist, MD a, Tara Rolstad, MBA f, David J. Margolis, MD, PhD a
Reprint requests: Joel M. Gelfand, MD, MSCE, 3600 Spruce St, 2 Maloney Bldg, Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104.Philadelphia, Pennsylvania; Boston, Massachusetts; Edegem, Belgium; Wake Forest, North Carolina; and Portland, Oregon
Abstract |
Background |
Psoriasis is a common disease with substantial effects on quality of life. The prevalence of psoriasis in African Americans has been previously reported as rare. However, there have been no population-based studies to assess the prevalence and burden of psoriasis in African Americans.
Objective |
We sought to measure the prevalence and burden of psoriasis in African Americans compared with Caucasians.
Methods |
Patients were randomly selected from the United States population and were asked standard demographic questions. Patients who reported a physician diagnosis of psoriasis were asked additional questions related to quality of life.
Results |
The total sample included 27,220 individuals of which 21,921 were Caucasian and 2443 were African American. The prevalence of psoriasis was 2.5% in Caucasian patients and was 1.3% in African American patients. African Americans had an approximately 52% reduction in the prevalence of psoriasis compared with Caucasians (P < .0001). African Americans and Caucasians had similar impacts on quality of life and treatment satisfaction based on single global questions.
Conclusion |
Although psoriasis is less common in African Americans than in Caucasians, it is not rare in either demographic and carries a substantial burden in both groups.
Le texte complet de cet article est disponible en PDF.Plan
| Dr Gelfand was supported by grants from the Dermatology Foundation; the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (K23 AR051125-01); and the American Skin Association. The Psoriasis Foundation gratefully acknowledges Biogen, Amgen, and Wyeth for their unrestricted grant to help make the survey possible. The Psoriasis Foundation was solely responsible for all survey content and development. Conflicts of interest: None identified. |
Vol 52 - N° 1
P. 23-26 - janvier 2005 Retour au numéro
Article précédent
- Answers to CME examination : Identification No. 805-101
- Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States
- Amit S. Kulkarni, Rajesh Balkrishnan, David Richmond, Daniel J. Pearce, Steven R. Feldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?